Investor Relations

About Us

PAVmed is a medical device company employing a business model to bring innovative products from concept to commercialization with speed and capital efficiency, while enhancing and accelerating value creation.

PAVmed is building a deep pipeline of products encompassing a broad spectrum of clinical areas possessing attractive regulatory pathways and market opportunities currently exceeding $4 billion.  The company currently has five lead products to provide multiple near-term value creation opportunities

The Company is led by a team of accomplished medical device entrepreneurs. The leadership team has previously successfully implemented its unique business model of creating value with modest capital investment in four single-product companies, each of which rapidly advanced towards commercialization. Two of these four products have been cleared and commercialized, while two products are currently undergoing FDA review. PAVmed leverages this unique business model.

By establishing a long-term multi-product company with access to public capital, the company plans to build an expanding pipeline of innovative products across a range of specialties and clinical conditions.

Recent Press Releases

  • 4/24/18 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product medical device company, today announced that it has signed a letter of intent with Case Western Reserve University to commercialize its groundbreaking EsoCheck technology. EsoCheck combines a non-invasive, cell-sampling device with highly accurate DNA biomarkers to detect Barrett’s Esophagus, the primary precursor of esophageal cancer. In a simple five-minutemore...
  • 4/11/18 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today reports financial results for the three and 12 months ended December 31, 2017 and provides a business update. Management Commentary “During the fourth quarter of 2017 and in recent months, PAVmed has continued to advance toward important regulatory and commercial milestones for its lead products,more...
  • 4/5/18 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced the final results of its previously disclosed offer to exchange each of its Series W Warrants (Nasdaq: PAVMW, the “Series W Warrant”) for 0.5 Series Z Warrants (the “Offer”). The Offer expired at 5:00 p.m. Eastern time on April 2, 2018. According to Continental Stock Transfer & Trust Company, themore...

In the News

  • Forbes
    11/7/16 5:13 pm EST

    Shares of small-capitalization companies have been busy beavers, besting larger-cap stocks since February after a long period of under-performance, with the Russell 2000 outscoring the S&P 500-stock index. And analysts point out that small-cap investing has proven to be the better play for the long term.

SEC Filings

Click Here to view PAVmed's SEC filings


Click Here to view PAVmed’s current Investor Presentation


Click Here to view the Proxy Statement for PAVmed Inc 2017 Annual Meeting

Click Here to view the Annual Report for PAVmed Inc 2017 Annual Meeting